Systemic enzyme therapy in the gout treatment
Kovalenko V.N.,
Siniatchenko O.V., Ignatchenko G.A., Terzov A.I., Grin V.K.,
Lauschkina E.M.Systemic enzyme therapy in the gout treatment.
Ukrainskii kardiologitschnyi zurnal 1998: 1, 53-56.
36
male patients suffering from primary gout were observed. Patients
received non-steroidal antiinflammatory drugs (diclofenac sodium,
movalis, phelden, indomethacin) and allopurinol (milurit).
Patients were randomly divided into two groups:
19 patients, aged 28-69
years (mean 48.9)
17 patients, aged 29-71
(mean 50.2)
Patients in the second
group received Wobenzym (5 dragees 3 times a day for 1 week, then
4x3 dragees for 7 days, and finally 3x3 dragees for 1 month) in the
complex therapy.
Before therapy and after 3
weeks, purine parameters were determined in the blood – uric acid,
oxypurinol, xanthine oxidase, 5-nucleotidase, adenosine deaminase,
glycine, glutamine, and aspartic acid.
The efficacy of articular
syndrome treatment in patients receiving Wobenzym reached 94.1% in
comparison to 47.3% in the control group. Even more obvious were
differences regarding renal syndrome.
While the conventional
gout treatment led to the decrease of only uric acid and xanthine
oxidase in the blood, inclusion of Wobenzym into the therapy caused
decrease of oxypurinol, 5-nucleotidase and adenosine deaminase
level.
Of special interest are
data concerning the investigation of serum dynamic interphase
tensometry before and after treatment of patients in both groups.
Administration of allopurinol and non-steroidal antiinflammatory
drugs evoked a suppression of surface tension in the region of
short, middle, and long surface life-time. This might be caused by
the accumulation of substances with surfactant properties.